Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
Oncolytic Newcastle disease virus (NDV) might be a promising new therapeutic agent for the treatment of pancreatic cancer. We evaluated recombinant NDVs (rNDVs) expressing interferon (rNDV-hIFNβ-F\(_{\rm{0}}\)) or an IFN antagonistic protein (rNDV-NS1-F\(_{\rm{0}}\)), as well as rNDV with increased...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-06-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/7/6/2756 |
id |
doaj-d45d7df8bedc473d938d9a4cf3123e1c |
---|---|
record_format |
Article |
spelling |
doaj-d45d7df8bedc473d938d9a4cf3123e1c2020-11-24T23:13:40ZengMDPI AGViruses1999-49152015-06-01762980299810.3390/v7062756v7062756Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic AdenocarcinomaPascal Buijs0Stefan van Nieuwkoop1Vincent Vaes2Ron Fouchier3Casper van Eijck4Bernadette van den Hoogen5Department of Surgery, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Surgery, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, The NetherlandsOncolytic Newcastle disease virus (NDV) might be a promising new therapeutic agent for the treatment of pancreatic cancer. We evaluated recombinant NDVs (rNDVs) expressing interferon (rNDV-hIFNβ-F\(_{\rm{0}}\)) or an IFN antagonistic protein (rNDV-NS1-F\(_{\rm{0}}\)), as well as rNDV with increased virulence (rNDV-F\(_{\rm{3aa}}\)) for oncolytic efficacy in human pancreatic adenocarcinoma cells. Expression of additional proteins did not hamper virus replication or cytotoxic effects on itself. However, expression of interferon, but not NS1, resulted in loss of multicycle replication. Conversely, increasing the virulence (rNDV-F\(_{\rm{3aa}}\)) resulted in enhanced replication of the virus. Type I interferon was produced in high amounts by all tumor cells inoculated with rNDV-hIFNβ -F\(_{\rm{0}}\), while inoculation with rNDV-NS1-F\(_{\rm{0}}\) resulted in a complete block of interferon production in most cells. Inoculation of human pancreatic adenocarcinoma cells with rNDV-F\(_{\rm{3aa}}\) caused markedly more cytotoxicity compared to rNDV-F\(_{\rm{0}}\), while inoculation with rNDV-hIFNβ -F\(_{\rm{0}}\) and rNDV-NS1-F\(_{\rm{0}}\) induced cytotoxic effects comparable to those induced by the parental rNDV-F\(_{\rm{0}}\). Evaluation \textit{in vivo} using mice bearing subcutaneous pancreatic cancer xenografts revealed that only intratumoral injection with rNDV-F\(_{\rm{3aa}}\) resulted in regression of tumors. We conclude that although lentogenic rNDVs harboring proteins that modulate the type I interferon pathway proteins do have an oncolytic effect, a more virulent mesogenic rNDV might be needed to improve oncolytic efficacy.http://www.mdpi.com/1999-4915/7/6/2756oncolytic virusoncolytic virotherapyNewcastle disease viruspancreatic adenocarcinomainnate immunityimmunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pascal Buijs Stefan van Nieuwkoop Vincent Vaes Ron Fouchier Casper van Eijck Bernadette van den Hoogen |
spellingShingle |
Pascal Buijs Stefan van Nieuwkoop Vincent Vaes Ron Fouchier Casper van Eijck Bernadette van den Hoogen Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma Viruses oncolytic virus oncolytic virotherapy Newcastle disease virus pancreatic adenocarcinoma innate immunity immunotherapy |
author_facet |
Pascal Buijs Stefan van Nieuwkoop Vincent Vaes Ron Fouchier Casper van Eijck Bernadette van den Hoogen |
author_sort |
Pascal Buijs |
title |
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma |
title_short |
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma |
title_full |
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma |
title_fullStr |
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma |
title_full_unstemmed |
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma |
title_sort |
recombinant immunomodulating lentogenic or mesogenic oncolytic newcastle disease virus for treatment of pancreatic adenocarcinoma |
publisher |
MDPI AG |
series |
Viruses |
issn |
1999-4915 |
publishDate |
2015-06-01 |
description |
Oncolytic Newcastle disease virus (NDV) might be a promising new therapeutic agent for the treatment of pancreatic cancer. We evaluated recombinant NDVs (rNDVs) expressing interferon (rNDV-hIFNβ-F\(_{\rm{0}}\)) or an IFN antagonistic protein (rNDV-NS1-F\(_{\rm{0}}\)), as well as rNDV with increased virulence (rNDV-F\(_{\rm{3aa}}\)) for oncolytic efficacy in human pancreatic adenocarcinoma cells. Expression of additional proteins did not hamper virus replication or cytotoxic effects on itself. However, expression of interferon, but not NS1, resulted in loss of multicycle replication. Conversely, increasing the virulence (rNDV-F\(_{\rm{3aa}}\)) resulted in enhanced replication of the virus. Type I interferon was produced in high amounts by all tumor cells inoculated with rNDV-hIFNβ -F\(_{\rm{0}}\), while inoculation with rNDV-NS1-F\(_{\rm{0}}\) resulted in a complete block of interferon production in most cells. Inoculation of human pancreatic adenocarcinoma cells with rNDV-F\(_{\rm{3aa}}\) caused markedly more cytotoxicity compared to rNDV-F\(_{\rm{0}}\), while inoculation with rNDV-hIFNβ -F\(_{\rm{0}}\) and rNDV-NS1-F\(_{\rm{0}}\) induced cytotoxic effects comparable to those induced by the parental rNDV-F\(_{\rm{0}}\). Evaluation \textit{in vivo} using mice bearing subcutaneous pancreatic cancer xenografts revealed that only intratumoral injection with rNDV-F\(_{\rm{3aa}}\) resulted in regression of tumors. We conclude that although lentogenic rNDVs harboring proteins that modulate the type I interferon pathway proteins do have an oncolytic effect, a more virulent mesogenic rNDV might be needed to improve oncolytic efficacy. |
topic |
oncolytic virus oncolytic virotherapy Newcastle disease virus pancreatic adenocarcinoma innate immunity immunotherapy |
url |
http://www.mdpi.com/1999-4915/7/6/2756 |
work_keys_str_mv |
AT pascalbuijs recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma AT stefanvannieuwkoop recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma AT vincentvaes recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma AT ronfouchier recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma AT caspervaneijck recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma AT bernadettevandenhoogen recombinantimmunomodulatinglentogenicormesogeniconcolyticnewcastlediseasevirusfortreatmentofpancreaticadenocarcinoma |
_version_ |
1725597264077914112 |